Home › NDC Lookup › RxCUI directory › RxCUI 2058830

7 ML cemiplimab-rwlc 50 MG/ML Injection — RxCUI 2058830

RxNorm drug concept · Semantic clinical drug
RxCUI 2058830 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2058830
Official name7 ML cemiplimab-rwlc 50 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known ascemiplimab-rwlc 350 MG per 7 ML Injection; cemiplimab-rwlc 350 MG in 7 ML Injection; cemiplimab-rwlc 50 MG/ML per 7 ML Injection
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)3,607 prescriptions · 32 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Cemiplimab-rwlc Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Libtayo is an immunotherapy — it doesn't kill cancer cells directly the way chemotherapy does. Instead, it helps your own immune system do the job. Cancer cells can produce a prote...
  • What exactly is Libtayo and how does it fight my cancer?
  • The most common side effects are fatigue, muscle or joint pain, rash, diarrhea, nausea, and itching — these are uncomfortable but manageable for most people. The ones to act on qui...
  • What side effects should I expect, and which ones mean I need to call someone right away?
📖 Read our full Cemiplimab-rwlc Injection guide →

🕸️ Concept Web — How 7 ML cemiplimab-rwlc 50 MG/ML Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 7 ML cemiplimab-rwlc 50 MG/ML Injection RxCUI 2058830

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Cemiplimab 2058826
    • Cemiplimab-rwlc 2058825
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Libtayo 2058831
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Cemiplimab Injection 2058829
    • Cemiplimab-rwlc Injection 2647344
    • Cemiplimab Injectable Product 2058828
    • Cemiplimab-rwlc Injectable Product 2659229
    • Cemiplimab Injection [Libtayo] 2058833
    • Cemiplimab-rwlc Injection [Libtayo] 2657678
    • Libtayo Injectable Product 2058834
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Cemiplimab-rwlc 50 MG/ML SCDC · 2058827
  • Cemiplimab Injection SCDF · 2058829
  • Cemiplimab-rwlc Injection SCDFP · 2647344
  • Cemiplimab Injectable Product SCDG · 2058828
  • Cemiplimab-rwlc Injectable Product SCDGP · 2659229

Brand-Name Concepts

  • 7 ML cemiplimab-rwlc 50 MG/ML Injection [Libtayo] SBD · 2058835
  • Cemiplimab-rwlc 50 MG/ML [Libtayo] SBDC · 2058832
  • Cemiplimab Injection [Libtayo] SBDF · 2058833
  • Cemiplimab-rwlc Injection [Libtayo] SBDFP · 2657678
  • Libtayo Injectable Product SBDG · 2058834
  • Libtayo BN · 2058831

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2058830 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
61755-0008-01 1 VIAL, SINGLE-USE in 1 CARTON (61755-008-01) / 7 mL in 1 V... LIBTAYO Regeneron Pharmaceuticals, Inc. 2018-09-28
Observed labelers: Regeneron Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9119 Inj., cemiplimab-rwlc, 1 mg 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.